# National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Phase 4 study closed enrollment, 121 enrolled (Diabetes Mellitus, Hepatitis C, Chronic)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Sponsor type | NIH |
| Study | People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents |
| NCT ID | NCT03520660 |
| Phase | Phase 4 |
| Status | active not recruiting |
| Conditions | Diabetes Mellitus; Hepatitis C, Chronic; Cardiovascular Diseases |
| Intervention types | drug |
| Target enrollment | 121 |
| Site countries | United States |
| Posted | 2018-05-11 |
| Planned start | 2018-10-19 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-22 |
| Last update posted | 2026-10-22 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- 121 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03520660). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.